Vir Biotechnology Inc Dossier
Qualitative Analysis
Business overview
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases and cancer. The company has assembled multiple technology platforms designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its clinical development pipeline includes investigational therapies targeting chronic hepatitis delta (CHD) and various solid tumors. Key pipeline candidates include tobevibart (an investigational neutralizing monoclonal antibody) and elebsiran (an investigational HBV-targeted siRNA). Additionally, Vir has pivoted significantly into oncology, leveraging its PRO-XTEN masking platform to develop conditionally activated T-cell engagers (TCEs) designed to target tumors while minimizing damage to healthy tissues.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing a portfolio of dual-masked T-cell engagers leveraging the proprietary PRO-XTEN technology to target solid tumors (including PSMA, HER2, and EGFR) while minimizing off-target toxicities.
Expected impact: Establishes a highly differentiated oncology pipeline with potential best-in-class therapeutics for prostate and other solid tumors.
Executing the ECLIPSE registrational clinical program (ECLIPSE 1, 2, and 3) to evaluate the combination of tobevibart and elebsiran as a potential functional cure for CHD.
Expected impact: Enables global regulatory submissions and commercialization in high-unmet-need markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Accelerates the clinical development and potential commercialization of VIR-5500, a PSMA-targeted dual-masked T-cell engager for metastatic castration-resistant prostate cancer (mCRPC).
Terms: Vir received $335 million in upfront and near-term payments (including $240 million cash and a $75 million equity investment). Vir is eligible for up to $1.37 billion in future milestones plus tiered double-digit royalties ex-U.S. Global development costs are split 40/60 (Vir/Astellas), and U.S. profits/losses are split 50/50.
Secures a commercialization partner with deep hepatology expertise to market the tobevibart and elebsiran combination therapy for chronic hepatitis delta in Europe, Australia, and New Zealand.
Terms: Vir received a EUR 55 million upfront reimbursement payment and is eligible for up to EUR 495 million in milestones, plus tiered mid-teen to high-twenties percent royalties. Norgine also contributes approximately 25% of go-forward external clinical development costs for the ECLIPSE program.